Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1840563 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $0.95Day +7.88%Mkt cap $4M1Y −99.5%Off 52W high −99.7%Vol (1Y) 258.3%
Daily closing price, split-adjusted to the current basis; 2.6y shown of 657 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest17.8% of sh out |
| Days to cover1.0d |
| Top-10 13F concentration100.0% |
| Next report (est.)2026-08-14 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Sales (TTM)$590,084 |
| Earnings (TTM)-$11.1M |
| ROE−106.9% |
| Net margin−1313.0% |
| Sales growth 3Y−8.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−97.3% |
| 1Y−99.5% |
| Since incept. (ann.)−99.2% |
Total return through 2026-07-30 · series begins 2023-11-21. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)258.3% |
| Ann. volatility (3Y)197.2% |
| Sharpe (1Y)−1.09 |
| Sharpe (3Y)−1.59 |
| Max drawdown (1Y)−99.6% |
| Max drawdown (3Y)−100.0% |
| Beta (3Y vs SPY)−0.31 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| JANE STREET GROUP, LLC | 31,594 | $189,248 | 0.70% | new |
| MORGAN STANLEY | 15,000 | $89,850 | 0.33% | new |
| Schonfeld Strategic Advisors LLC | 14,800 | $88,652 | 0.33% | new |
| IFP Advisors, Inc | 2,000 | $11,980 | 0.04% | new |
| UBS Group AG | 1,302 | $7,799 | 0.03% | new |
| Tower Research Capital LLC (TRC) | 129 | $773 | 0.00% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | — | — | $681,994 | — |
| 2025-09-30 | 2025-11-14 | — | — | $285,948 | −45.8% |
| 2024-09-30 | 2024-11-14 | — | — | $527,478 | −4.9% |
| 2024-06-30 | 2024-08-14 | — | — | $605,529 | +91.3% |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-14 is ESTIMATED from filing cadence (median gap 91d) — not company-confirmed.
